Currently in Phase III of clinical trials, eneboparatide has shown promise in normalizing key calcium levels and improving ...

“We believe FDA’s granting of fast track designation to eneboparatide reflects the agency’s recognition of the significant ...

CHRONIC idiopathic hypoparathyroidism is a rare disease that may be identified if the clinical features of chronic tetany are recognized and confirmed by appropriate chemical and ...

Expert Rev Endocrinol Metab. 2012;7(3):255-257. The future of hormone replacement therapy in hypoparathyroidism can be viewed with optimism, even if we are left with several unanswered questions ...

Hypoparathyroidism (hypoPARA) is a rare endocrine disease resulting from the absence or deficiency of parathyroid hormone (PTH), which can lead to multi-organ complications, including renal ...

The Ajmera Transplant Centre at University Health Network (UHN) has performed a groundbreaking parathyroid transplant, in a patient who suffered from a severe form of hypoparathyroidism – when ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for YORVIPATH ® ...

Background: Some of the patients with idiopathic hypoparathyroidism (IHP) report symptoms of hypocalcemia during menstruation. There is limited data on this observation. Methods: Twenty six ...

Danish pharmaceutical company Ascendis Pharma A/S (ASND) announced that the United Kingdom's Medicines & Healthcare products ...

Fibrin sealant may reduce length of hospitalization and operative time among patients undergoing thyroidectomy suggests a ...

TORONTO, ON, May 01, 2024 (GLOBE NEWSWIRE) --. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has ...

The orphan status provides 10 years of market exclusivity in Great Britain with respect to similar medicinal products in the approved orphan indication of chronic adult hypoparathyroidism.